CarlosAlonso,Manuel Soto
258
ACKNOWLEDGEMENTS
This reviewgathersdata fromalreadypublishedpaper. Itwas supportedby
grants from Ministerio de Ciencia e Innovación FIS PI11/00095 and from the
InstitutodeSaludCarlos IIIwithintheNetworkofTropicalDiseasesResearch(VIP
I+D+I 2008-‐2011, ISCIII -‐SubdirecciónGeneral deRedesyCentrosde Investigación
Cooperativa (RD12/0018/0009)). Funding from Laboratorios Leti and an
institutional grant fromFundaciónRamónArecesarealsoacknowledged.
REFERENCES
1 Mauricio, I. L.; Stothard, J. R.; Miles, M. A. The strange case of
Leishmania chagasi
.
ParasitologyToday
16,
188-‐189(2000).
2 Murray, H.W.; Berman, J. D.; Davies, C. R.; Saravia, N. G. Advances inLeishmaniasis. Lancet
366
, 1561-‐1577(2005).
3 Herwaldt, B. L. Leishmaniasis. Lancet
354,
1191-‐1199(1999).
4 Mutiso, J. M.; Macharia, J. C.; Kiio, M. N.; Ichagichu, J. M.; Rikoi, H.; Gicheru, M. M.
Development of
Leishmania
vaccines: predicting the future from past and present
experience. Journal ofBiomedical Research
27
, 85-‐102(2013).
5 Gramiccia, M.; Gradoni, L. The current status of zoonotic leishmaniases and approaches to
diseasecontrol. International Journal of Parasitology
35,
1169-‐1180(2005).
6 Reis, A. B.; Giunchetti, R. C.; Carrillo, E.; Martins-‐Filho, O. A.; Moreno, J. Immunity to
Leishmania
and the rational search for vaccines against canine leishmaniasis. Trends in
Parasitology
26
, 341-‐349(2010).
7 Baneth, G.; Koutinas, A. F.; Solano-‐Gallego, L.; Bourdeau, P.; Ferrer, L. Canine leishmaniosis:
newconcepts and insights on an expanding zoonosis: part one. Trends inParasitology
24
,
324-‐330(2008).
8 Murray, H. W. Endogenous interleukin-‐12 regulates acquired resistance in experimental
visceral leishmaniasis. The Journal of InfectiousDiseases
175
, 1477-‐1479(1997).
9 de Oliveira, C. I.; Brodskyn, C. I. The immunobiology of
Leishmania braziliensis
infection.
Frontiers in Immunology
3
, 145(2012).
10 Bertholet, S.; Goto, Y.; Carter, L.; Bhatia, A.;Howard, R. F.; Carter, D.; Coler, R. N.; Vedvick, T.
S.; Reed, S. G. Optimized subunit vaccine protects against experimental leishmaniasis.
Vaccine
27
, 7036-‐7045(2009).
11 Beaumier, C. M.; Gillespie, P. M.; Hotez, P. J.; Bottazzi, M. E. New vaccines for neglected
parasiticdiseases anddengue. Translational Research
162
, 144-‐155(2013).
12 Dantas-‐Torres, F. Leishmune vaccine: thenewest tool for preventionand control of canine
visceral leishmaniosis and its potential as a transmission-‐blocking vaccine. Veterinary
Parasitology
141
, 1-‐8(2006).
13 Fernandes, A. P.; Coelho, E. A.; Machado-‐Coelho, G. L.; Grimaldi, G., Jr.; Gazzinelli, R. T.
Making an anti-‐amastigote vaccine for visceral leishmaniasis: rational, update and
perspectives. CurrentOpinion inMicrobiology
15
, 476-‐485(2012).
14 Bongiorno, G.; Paparcone, R.; Manzillo, V. F.; Oliva, G.; Cuisinier, A. M.; Gradoni, L.
Vaccination with LiESP/QA-‐21 (CaniLeish) reduces the intensity of infection in
Phlebotomus perniciosus
fed on
Leishmania infantum
infected dogs-‐A preliminary
xenodiagnosis study. VeterinaryParasitology
97
691-‐695(2013).
15 Moreno, J.; Vouldoukis, I.; Martin, V.; McGahie, D.; Cuisinier, A. M.; Gueguen, S. Use of a
LiESP/QA-‐21vaccine (CaniLeish) stimulates an appropriateTh1-‐dominated cell-‐mediated
immune response indogs. PLoSNeglectedTropicalDiseases
6
, e1683(2012)
16 Melby, P. C.; Yang, Y. Z.; Cheng, J.; Zhao, W. Regional differences in the cellular immune
response to experimental cutaneous or visceral infection with
Leishmania donovani
.
Infectionand Immunity
66
, 18-‐27(1998).
17 de Oliveira, C. I.; Nascimento, I. P.; Barral, A.; Soto, M.; Barral-‐Netto, M. Challenges and
perspectives in vaccination against leishmaniasis. Parasitology International
58
, 319-‐324
(2009).
